IDO2 and neoplasm: As TDO appears to be up-regulated in more cancer types than has hitherto been assumed and appears to be a prognostic factor in patient survival, tumour tissues should be assessed for TDO2 in addition to IDO1 and IDO2 before embarking on mono or multiple therapies with inhibitors of these enzymes.